Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 53

Sort by

Sort Order Select

Journal Articles

The presence of SH2B3 mutations identifies a distinct subtype of myelodysplastic neoplasms

Blood (2025) 146 (Supplement 1): 2070.

https://doi.org/10.1182/blood-2025-2070

Published: 2025

Journal Articles

Efficacy and safety results from the primary analysis of the pivotal summit trial: Bezuclastinib in adults with non-advanced systemic mastocytosis

Lindsay Rein, Nathan Boggs, Prithviraj Bose, Brian Modena, Vito Sabato, Karin Hartmann, Cem Akin, Tracy George, Cecilia Arana Yi, Hanneke Oude Elberink, Deepti Radia, Andreas Reiter, Miguel Piris-Villaespesa, Ingunn Dybedal, Jens Panse, Stephen Oh, Pankit Vachhani, Anthony Hunter, Mariana Castells, Cristina Bulai Livideanu, Paul van Daele, Arnold Kirshenbaum, Ivan Alvarez-Twose, Jennifer Vaughn, Minakshi Taparia, Sonia Cerquozzi, Andrzej Mital, Marek Hus, ALESSANDRA ROMANO, John Fahrenholz, Frederick Lansigan, Cristina Papayannidis, Helena Pomares, Michela Rondoni, Celalettin Ustun, Richard Herrscher, Michael Manning, Stéphane Barete, Mar Guilarte, Candido Rivera, Jonathan Bernstein, Peter Vadas, Chiara Elena, Derek McCulloch, Nina Orfali, Clodagh Keohane, Francesco Mannelli, Philippe Schafhausen, Amanda Pilla, Jenna Zhang, Lei Sun, Nisha Shah, Hina Jolin, Rachael Easton, Jessica Sachs, Frank Siebenhaar, Daniel Deangelo

Blood (2025) 146 (Supplement 1): 80.

https://doi.org/10.1182/blood-2025-80

Published: 2025

Journal Articles

EZH2 molecular alterations drive micromegakaryocyte expansion in MDS defining a specific high-risk group

Blood (2025) 146 (Supplement 1): 2084.

https://doi.org/10.1182/blood-2025-2084

Published: 2025

Journal Articles

Better discriminative capacity of blast and blast-mol scores in chronic myelomonocytic leukemia (CMML)

Blood (2025) 146 (Supplement 1): 2083.

https://doi.org/10.1182/blood-2025-2083

Published: 2025

Journal Articles

Real-world insights into venetoclax and/or hypomethylating agent discontinuation in patients with Acute Myeloid Leukemia

Blood (2025) 146 (Supplement 1): 5232.

https://doi.org/10.1182/blood-2025-5232

Published: 2025

Journal Articles

Incidence and molecular underpinnings of donor-cell derived neoplasm among spanish transplantation centers

Blood (2025) 146 (Supplement 1): 4275.

https://doi.org/10.1182/blood-2025-4275

Published: 2025

Journal Articles

Allogeneic transplantation and frontline therapy shape survival outcomes in secondary AML: Real-world epidemiology and prognostic insights

Rosa Coll, Nuria Brey, Antonella Luciana Sturla, Jordi Viñas, Montserrat Arnan, Helena Pomares, Susana Vives, Anna Sureda Balarí, Juan-Manuel Sancho, David Gallardo

Blood (2025) 146 (Supplement 1): 6896.

https://doi.org/10.1182/blood-2025-6896

Published: 2025

Journal Articles

Impact of Transfusion Dependency on Patients Diagnosed with Myelodysplastic Syndrome According to IPSS-M Risk Group

Blood (2024) 144 (Supplement 1): 1838.

https://doi.org/10.1182/blood-2024-205407

Published: 2024

Journal Articles

Apex Part 2 Trial in Progress: A Phase 2 Open-Label Clinical Study of Bezuclastinib in Adult Patients with Advanced Systemic Mastocytosis

Blood (2024) 144 (Supplement 1): 4569.1.

https://doi.org/10.1182/blood-2024-194550

Published: 2024

Journal Articles

Apex Part 1: Updated Assessment of Bezuclastinib (CGT9486), a Selective KIT D816V Tyrosine Kinase Inhibitor, in Patients with Advanced Systemic Mastocytosis (AdvSM)

Blood (2024) 144 (Supplement 1): 659.

https://doi.org/10.1182/blood-2024-193678

Published: 2024

Journal Articles

Donor Cell-Derived Hematologic Neoplasms: Role of Germline Predisposition and Clonal Hematopoiesis

Blood (2024) 144 (Supplement 1): 597.

https://doi.org/10.1182/blood-2024-207189

Published: 2024

Journal Articles

The Presence of SH2B3 mutations Identifies a Distinct Subtype of Myelodysplastic Neoplasms

Blood (2024) 144 (Supplement 1): 3214.

https://doi.org/10.1182/blood-2024-194488

Published: 2024

Journal Articles

Evaluating Molecular and Clinical Predictors in Myelodysplastic Syndromes through Machine Learning Integration

Blood (2024) 144 (Supplement 1): 6683.

https://doi.org/10.1182/blood-2024-198114

Published: 2024

Journal Articles

Pre-Transplant Diabetes Is Associated with Increased Risk of Relapse after HCT: A Single Center Experience

Annalisa Paviglianiti, Marta Bellver Sanchis, Marta Peña, Inmaculada Peiro Martinez, Felipe Peña, Lidia Hurtado, Raquel Lopez Gil, Alberto Mussetti, Montserrat Arnan, Helena Pomares, Eva Gonzalez Barca, Patricia Lopez Pereira, Rocky Strollo, Paolo Pozzilli, Anna Sureda Balari

Blood (2024) 144 (Supplement 1): 7412.

https://doi.org/10.1182/blood-2024-198124

Published: 2024

Journal Articles

Prognostic Value of the Measurable Residual Disease (MRD) in AML Treatment with Venetoclax in Combination with Hypomethylating Agents: Validation of the ELN 2021 MRD Recommendations

Blood (2024) 144 (Supplement 1): 225.

https://doi.org/10.1182/blood-2024-204503

Published: 2024

Journal Articles

Genomic Instability in Early-Onset Myelodysplastic Syndrome Patients Harboring Rare Germline Variants in NHEJ DNA Repair Genes

Blood (2024) 144 (Supplement 1): 2708.

https://doi.org/10.1182/blood-2024-211133

Published: 2024

Journal Articles

Prognostic Impact of Complex Karyotype in Acute Promyelocytic Leukemia

Julia Ribes-Amoros, Helena Pomares, Susana Vives, Nuria Brey, Jordi Verge, Rosa Coll, Marta Cervera, Elena Bechtold Javier, Shiomara Quiñones, Maria Isabel Sotelo, Mercedes Galiano, Esther Alonso, Anna Sureda Balari, Lurdes Zamora, Isabel Granada, Montserrat Arnan

Blood (2024) 144 (Supplement 1): 6138.

https://doi.org/10.1182/blood-2024-205868

Published: 2024

Journal Articles

Assessment of the IPSS-M in Chronic Myelomonocytic Leukemia

Blood (2024) 144 (Supplement 1): 3205.

https://doi.org/10.1182/blood-2024-204557

Published: 2024

Journal Articles

Clinical Characteristics of Patients with TP53 Multihit MDS and AML. a Single-Center Experience

Jasson Villarreal Hernandez, Helena Pomares, Antonella Sturla, Esther Alonso, Clara Maluquer Artigal, Rebecca Andersson, María Alicia Senin, Maria Teresa Encuentra, Mercedes Galiano, Lurdes Zamora, Marta Cabezón, Neus Ruiz Xiville, Maria Carolina Florian, Anna Maria Sureda Balari, Montserrat Arnan Sangerman

Blood (2023) 142 (Supplement 1): 5868.

https://doi.org/10.1182/blood-2023-187430

Published: 2023

Journal Articles

Venetoclax and Azacytidine Treatment for High Risk Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia As a Bridge Therapy to Transplant. a GESMD Study

Blood (2023) 142 (Supplement 1): 1858.

https://doi.org/10.1182/blood-2023-186777

Published: 2023

Update search

NARROW

Publications

Format

Article Type

Topics

Date

Availability

The presence of SH2B3 mutations identifies a distinct subtype of myelodysplastic neoplasms

Efficacy and safety results from the primary analysis of the pivotal summit trial: Bezuclastinib in adults with non-advanced systemic mastocytosis

EZH2 molecular alterations drive micromegakaryocyte expansion in MDS defining a specific high-risk group

Better discriminative capacity of blast and blast-mol scores in chronic myelomonocytic leukemia (CMML)

Real-world insights into venetoclax and/or hypomethylating agent discontinuation in patients with Acute Myeloid Leukemia

Incidence and molecular underpinnings of donor-cell derived neoplasm among spanish transplantation centers

Allogeneic transplantation and frontline therapy shape survival outcomes in secondary AML: Real-world epidemiology and prognostic insights

Impact of Transfusion Dependency on Patients Diagnosed with Myelodysplastic Syndrome According to IPSS-M Risk Group

Apex Part 2 Trial in Progress: A Phase 2 Open-Label Clinical Study of Bezuclastinib in Adult Patients with Advanced Systemic Mastocytosis

Apex Part 1: Updated Assessment of Bezuclastinib (CGT9486), a Selective KIT D816V Tyrosine Kinase Inhibitor, in Patients with Advanced Systemic Mastocytosis (AdvSM)

Donor Cell-Derived Hematologic Neoplasms: Role of Germline Predisposition and Clonal Hematopoiesis

The Presence of SH2B3 mutations Identifies a Distinct Subtype of Myelodysplastic Neoplasms

Evaluating Molecular and Clinical Predictors in Myelodysplastic Syndromes through Machine Learning Integration

Pre-Transplant Diabetes Is Associated with Increased Risk of Relapse after HCT: A Single Center Experience

Prognostic Value of the Measurable Residual Disease (MRD) in AML Treatment with Venetoclax in Combination with Hypomethylating Agents: Validation of the ELN 2021 MRD Recommendations

Genomic Instability in Early-Onset Myelodysplastic Syndrome Patients Harboring Rare Germline Variants in NHEJ DNA Repair Genes

Prognostic Impact of Complex Karyotype in Acute Promyelocytic Leukemia

Assessment of the IPSS-M in Chronic Myelomonocytic Leukemia

Clinical Characteristics of Patients with TP53 Multihit MDS and AML. a Single-Center Experience

Venetoclax and Azacytidine Treatment for High Risk Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia As a Bridge Therapy to Transplant. a GESMD Study

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only